Chemical Works Of Gedeon Richter Plc · BET:RICHTER
Chemical Works Of Gedeon Richter — Gedeon Richter — M9 2021 Earnings Presentation
18 slides from Chemical Works Of Gedeon Richter's earnings presentation, Nov 8, 2021
Slide 1: Richter Group Report, M9 2021
Richter Group Report, M9 2021 Budapest, 8 November 2021
Slide 2: Highlights I.
Report, M9 2021 Highlights I. 454,321 HUFm 55.5% Consolidated Gross margin sales +9.1% 20.7% 501 HUF Operating margin EPS +12.1% 93,108 HUFm Net profit* +12.0% * Net income attributable to owners of the parent. 2
Slide 3: Highlights II.
Report, M9 2021 Central Nervous System Highlights II. 29 October 2021 - cariprazine AbbVie announced top-line results from two Phase 3 clinical trials, evaluating the efficacy and safety of cariprazine (Vraylar®) as an adjunctive treatment for patients with major depressive disorder (MDD). In one of
Slide 4: Corporate matters
Report, M9 2021 Other 11 August 2021 – Change in ownership structure Corporate matters Richter informed its shareholders that according to the notice received from Hungarian National Asset Management Incorporated (hereinafter “HNMA Inc.”) on 10 August 2021 in Gedeon Richter Plc. the influence (owner
Slide 5: Reconciliation of consolidated sales by segments
Report, M9 2021 HUFm Increase Decrease Total Reconciliation of consolidates sales by segments (HUFm) The pharma segment accounts for 80% of consolidated turnover. The share of sales in Pharma segment declined within the Group. Exchange rate loss at consolidated sales level: HUF 4,800m 5
Slide 6: Revenue by strategic pillars
Report, M9 2021 Revenue by strategic pillars (%) 2021 M9 27% 12% 34% 21% 6% Branded Traditionals WHC Cariprazine Biosimilars generics 2020 M9 28% 13% 34% 20% 5% 6
Slide 7: Change in the turnover of our selected products
Report, M9 2021 HUFm Increase Decrease Total Change in the turnover of our selected products Turnover of Vraylar® showed a robust growth in the third quarter 2021. When adjusting the base period figure for the sales related milestone received, year-on-year growth of royalties accounted for on behalf
Slide 8: Key products (1/2)
Report, M9 2021 Key products (1/2) Cariprazine USA - Reagila® HUF 74,329m HUF 71,252m Vraylar® (EUR 208.6m) Greece (Recordati), royalty income Australia (Seqirus), Unites (increase of 26.0% yoy) Arab Emirates (Hikma) – Turnover +10.7%* market launches Completed phase III * Significant milestone inco
Slide 9: Key products (2/2)
Report, M9 2021 Key products (2/2) Bemfola® Improving sales occurred as most of HUF 14,983m the fertility centers resumed their (EUR 42.1m) activities in many European countries. +28.0% The robust increase was partly due to Nőgyógyászat the exceptionally weak first nine Turnover months of 2020. WHC
Slide 10: Sales by geographies (%)
Report, M9 2021 Sales by geographies (%) HUF 363.7bn M9 2021 25% 8% 31% 24% 12% CIS Hungary Europe USA Other global +6.9% markets* M9 2020 27% 9% 30% 24% 10% HUF 340.4bn * Including the regions of China, Latin America and Rest of the World. 10
Slide 11: Change in turnover by geographies
Report, M9 2021 Increase Decrease HUFm Total Change in turnover by geographies In Europe substantial increases of Bemfola®, Terrosa® and royalty proceeds of Evra® resulted in an outstanding sales level. In the USA Vraylar®-related revenues grew marginally besides a one-off milestone payment last yea
Slide 12: Financials – Consolidated Highlights
Report, M9 2021 Consolidated Financials – Highlights as % of HUFbn Change % EURm total revenues Total revenue 454.3 9.1 1,275.3 Gross profit 252.2 6.6 707.8 55.5 Profit from operations 93.9 14.2 263.7 20.7 Profit for the period* 93.1 12.0 261.4 20.5 HUF Change % EUR EPS (diluted) 501 12.1 1.41 * Net
Slide 13: Increasing gross profit and decreasing margin
Report, M9 2021 HUFbn Increasing 600 62% Significant increase in royalties received 56.8% gross profit and 500 55.5% 61% in respect of the sales of Vraylar® (HUF 14,694m) decreasing margin 60% 400 (HUFbn) 59% Royalty in respect of Evra® has appeared 300 58% as a new element (HUF 9,704m) 57% 200 56%
Slide 14: S&M costs (HUFm)
Report, M9 2021 S&M costs HUFm (HUFm) 140 000 60% 120 000 50% 100 000 40% 80 000 30% 60 000 20% 40 000 10% 20 000 0 0% 2016 2017 2018 2019* 2020* M9 2020* M9 2021 S&M costs S&M percentage of sales * Reclassification of depreciation of intangible assets representing sales and other product-related li
Slide 15: R&D costs (HUFm) and split of R&D spending
Report, M9 2021 HUFm 60 000 15% R&D costs (HUFm) 50 000 40 000 10% 30 000 20 000 5% 10 000 0 0% 2016 2017 2018 2019 2020 M9 2020 M9 2021 R&D costs R&D percentage of sales Split of R&D spending (%) – M9 2021 CNS original Biosimilars WHC Branded generic research (including and traditional cariprazine)
Slide 16: Increasing operating profit and margin
Report, M9 2021 HUFm Increasing operating 120 000 20.7% 25% profit and margin 19.8% Significant Vralyar® royalty 100 000 (HUFm) 20% 80 000 Marketing and admin expenses 15% increased slightly however their 60 000 proportion to turnover reduced 10% 40 000 5% 20 000 The share of sales in the pharmaceut
Slide 17: Reconciliation of pharma segment operating profit
Report, M9 2021 HUFm Increase Decrease Total Reconciliation of pharma segment operating profit 17
Slide 18: RICHTER GEDEON
RICHTER GEDEON